EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Role of the ADAM33 rs2280091 Variant in Modulating Lung Function in Cystic Fibrosis

Vinícius Santiago Dos Santos iD, Lucas Silva Mello iD, Luiz Felipe Azevedo Marques iD, Luana Rodrigues Silva iD, Carmen Sílvia Bertuzzo iD, José Dirceu Ribeiro iD, Fernando Augusto Lima Marson iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms262311583 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Vinícius Santiago Dos Santos und 6 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Biology and Genetics, Postgraduate Program of Health Sciences, Postgraduate Program of Health Data Science, University of São…. Hauptthemen laut MEDLINE: Cystic Fibrosis, ADAM Proteins, Polymorphism, Single Nucleotide, Lung. Die Arbeit nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, National Council for Scientific and Technological Development, São Paulo Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cystic fibrosis (CF) is a rare genetic disease caused by pathogenic variants in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene, with wide clinical variability influence not only by the CFTR genotype but also by environmental and modifier genes such as ADAM33 (A Disintegrin and Metalloproteinase Domain 33). The rs2280091 variant in ADAM33 may affect lung function and contribute to differences in disease severity. This study investigated the association between this genetic variant and lung function in CF patients. This cross-sectional study included 55 CF patients from a Brazilian center, with diagnosis confirmed by sweat testing and CFTR genotyping. Pulmonary function was evaluated by spirometry before and after bronchodilator (BD) administration according to the American Thoracic Society/European Respiratory Society guidelines, analyzing Forced Vital Capacity (FVC), Forced Expiratory Volume in one second (FEV1), FEV1/FVC ratio, Forced Expiratory Flow at 25%, 50%, and 75% of FVC (FEF25%, FEF50%, and FEF75%), mean Forced Expiratory Flow between 25% and 75% of FVC (FEF25–75%), and Maximal Expiratory Forced Flow (MEF). The ADAM33 rs2280091 variant was genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), and statistical analyses included Kruskal–Wallis and Mann–Whitney tests, chi-square (χ2) tests, and calculation of odds ratios (ORs) with 95% confidence intervals (95% CI). The study included 55 CF patients, predominantly female (96.4%) and Caucasian (52.7%), with a median age of 17 years. CFTR genotyping revealed F508del/F508del as the most common genotype (52.7%). Analysis of the ADAM33 rs2280091 variant demonstrated that the AA genotype was most frequent in both CF patients (69.1%) and healthy controls (78.6%). Notably, the GG genotype was significantly enriched in CF patients (18.2%) compared with the controls (0.02%), yielding an odds ratio of 12.06 (95% CI: 4.86–29.91), while the G allele was also associated with increased disease risk (24.5% vs. 11.6%). Pulmonary function assessment indicated that carriers of the GG genotype or G allele had higher Forced Expiratory Flow parameters (FEF25%, FEF50%, FEF25–75%, and MEF) and improved BD responsiveness, suggesting a potential modulatory role of ADAM33 in peripheral airway function in CF. The G allele of the ADAM33 rs2280091 variant was more frequent among recruited CF patients and associated with improved peripheral airway function and BD response. These findings may reflect a survivor effect, in which carriers of this allele are more likely to reach clinical follow-up and recruitment rather than indicating a direct association with increased disease risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisADAM ProteinsPolymorphism, Single NucleotideLungHumansFemaleMaleAdultAdolescentCross-Sectional StudiesYoung AdultCystic Fibrosis Transmembrane Conductance RegulatorGenotypeRespiratory Function TestsChildGenetic Predisposition to Disease

Stichwörter der Autor:innen

airway remodelingcystic fibrosis phenotypegeneticgenetic association studiesmodifier genespolymorphismpulmonary function tests

Substanzen

ADAM33 protein, humanADAM ProteinsCystic Fibrosis Transmembrane Conductance RegulatorCFTR protein, human

Autor:innen und Institutionen

  • Laboratory of Molecular Biology and Genetics, Postgraduate Program of Health Sciences, Postgraduate Program of Health Data Science, University of São Francisco (Universidade São Francisco-USF), Bragança Paulista 12916-9…
  • Laboratory of Clinical and Molecular Microbiology, Postgraduate Program of Health Sciences, Postgraduate Program of Health Data Science, University of São Francisco (Universidade São Francisco-USF), Bragança Paulista 12…
  • LunGuardian Research Group-Epidemiology of Respiratory and Infectious Diseases, Postgraduate Program of Health Sciences, Postgraduate Program of Health Data Science, University of São Francisco (Universidade São Francis…
  • Department of Pediatrics, University of Campinas (Universidade de Campinas-Unicamp), Campinas 13083-970, SP, Brazil.

ORCID-Profile: Vinícius Santiago Dos Santos, Lucas Silva Mello, Luiz Felipe Azevedo Marques, Luana Rodrigues Silva, Carmen Sílvia Bertuzzo, José Dirceu Ribeiro, Fernando Augusto Lima Marson

Förderung

  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • National Council for Scientific and Technological Development
  • São Paulo Research Foundation
  • FAPESP
  • CNPq

Zitieren

APA

Dos Santos, V. S., Mello, L. S., Marques, L. F. A., Silva, L. R., Bertuzzo, C. S., Ribeiro, J. D., & Marson, F. A. L. (2025). Role of the ADAM33 rs2280091 Variant in Modulating Lung Function in Cystic Fibrosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262311583

Vancouver

Dos Santos VS, Mello LS, Marques LFA, Silva LR, Bertuzzo CS, Ribeiro JD, et al. Role of the ADAM33 rs2280091 Variant in Modulating Lung Function in Cystic Fibrosis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262311583

BibTeX
@article{DosSantos2025,
  author = {Dos Santos, Vinícius Santiago and Mello, Lucas Silva and Marques, Luiz Felipe Azevedo and Silva, Luana Rodrigues and Bertuzzo, Carmen Sílvia and Ribeiro, José Dirceu and Marson, Fernando Augusto Lima},
  title = {Role of the ADAM33 rs2280091 Variant in Modulating Lung Function in Cystic Fibrosis},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms262311583}
}
Kostenlos starten →